(Q37122486)

18 August 2017

1 reference

title

Dopamine, the dopamine D2 receptor and pituitary tumours (English)

1 reference

18 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

6 December 2022

author name string

D. F. Wood

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1837503

6 December 2022

J. M. Johnston

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1837503

6 December 2022

D. G. Johnston

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1837503

6 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1837503

6 December 2022

publication date

1 December 1991

1 reference

full work available at URL

18 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2265.1991.tb00928.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.1991.tb00928.x/fullpdf

6 December 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

6 December 2022

published in

Clinical Endocrinology

1 reference

18 August 2017

volume

35

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

455-466

1 reference

Dopamine receptor subtypes: beyond the D1/D2 classification

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Excitatory amino acids inhibit stimulation of phosphatidylinositol metabolism by aminergic agonists in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

G-protein subunits. Who carries what message?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

The GTPase superfamily: a conserved switch for diverse cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

The GTPase superfamily: conserved structure and molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Cloning and expression of a rat D2 dopamine receptor cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Potassium channels involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Prolactin and growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

D2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Cloning of the cDNA and gene for a human D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Molecular model of the G protein alpha subunit based on the crystal structure of the HRAS protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Bromocriptine therapy for "nonfunctioning" pituitary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Multiple receptors for dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Regulation and molecular characterization of dopamine D2 receptors in a prolactin-secreting 7315a anterior pituitary tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Two G protein oncogenes in human endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Multiple D2 dopamine receptors produced by alternative RNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Eukaryotic Transcriptional Regulation and Chromatin-Associated Protein Phosphorylation by Cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Roles of G protein subunits in transmembrane signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Structure of the adrenergic and related receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Hyperprolactinaemia in men-response to bromocriptine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Signal sorting and amplification through G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Pituitary hyperplasia. Definition, light and electron microscopical structures and significance in surgical specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Catecholamines of supposed inhibitory hypophysiotrophic function suppress action potentials in prolactin cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

The role of G proteins in transmembrane signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Mechanisms of signal transduction at the dopamine D2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

D2 receptor, a missing exon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Gasp: not just another oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.1991.TB00928.X

Hormone Secretion by Dispersed Cell Cultures of Human Pituitary Adenomas: Effects of Theophylline, Thyrotropin-Releasing Hormone, Somatostatin, and 2-Bromo-α-Ergocryptine*

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Growth hormone and prolactin secretion by dispersed cell cultures of a normal human pituitary: effects of thyrotrophin releasing hormone, theophylline, somatostatin, and 2-bromo-α-ergocryptine

6 December 2022

2

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clinically nonfunctioning pituitary tumors are monoclonal in origin

6 December 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopaminergic regulation of growth hormone (GH) secretion in normal man: correlation of L-dopa and dopamine levels with the GH response

6 December 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopaminergic stimulation and inhibition of growth hormone secretion in normal man: studies of the pharmacologic specificity

6 December 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery

6 December 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.

6 December 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors

6 December 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings

6 December 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

6 December 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine

6 December 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

TRH and Dopamine Interactions Affecting Pituitary Hormone Secretion

6 December 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series

6 December 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Changes in Plasma Growth Hormone Levels in Normal and Acromegalic Subjects Following Administration of 2-Bromo-α-Ergocryptine

6 December 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma

6 December 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Mammotroph and gonadotroph volume percentage in the rat anterior pituitary after lesions of the medial basal hypothalamus

6 December 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine

6 December 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture

6 December 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The 7315a Pituitary Tumor Is Refractory to Dopaminergic Inhibition of Prolactin Release But Contains Dopamine Receptors*

6 December 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Suppression of prolactin release and mRNA accumulation by two novel dopamine agonist agents

6 December 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

A family of receptors coupled to guanine nucleotide regulatory proteins

6 December 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Association of two pertussis toxin-sensitive G-proteins with the D2-dopamine receptor from bovine striatum

6 December 2022

41

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Biochimica et Biophysica Acta

6 December 2022

44

458

283

Fialkow P.J

1986

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors

6 December 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Hypothyroid pituitary cells in culture: an analysis of thyrotropin and prolactin responses to dopamine (DA) and DA receptor binding.

6 December 2022

47

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment

6 December 2022

48

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Management of hyperprolactinaemic amenorrhoea

6 December 2022

49

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

American Journal of Human Genetics

6 December 2022

52

45

778

Grandy O.K.

1989

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

6 December 2022

Prolactinomas

54

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The effect of dopamine agonist therapy on large functionless pituitary tumours.

6 December 2022

55

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects

6 December 2022

56

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Effects of Culture Age on PRL and GH Responses to Bromocriptine and Somatostatin from Primary Cultures of Rat Anterior Pituitary Cells

6 December 2022

57

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clonal origin of pituitary adenomas

6 December 2022

58

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia

6 December 2022

60

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The electrical properties of isolated human prolactin-secreting adenoma cells and their modification by dopamine

6 December 2022

61

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Modulation by Dopamine Antagonists of DNA Synthesis in the Pituitary Gland of the Male Rat

6 December 2022

62

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Deglycosylation and proteolysis of photolabeled D2 dopamine receptors of the porcine anterior pituitary

6 December 2022

63

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The G-protein family and their interaction with receptors

6 December 2022

64

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Hyperprolactinemia. Long-term effects of bromocriptine

6 December 2022

66

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The dopamine D2 receptor is expressed in GH3 cells

6 December 2022

67

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Reduction in size of prolactin-secreting tumours in men treated with pergolide

6 December 2022

69

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Luteinizing hormone-secreting pituitary tumor: biosynthetic characterization and clinical studies

6 December 2022

70

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors

6 December 2022

71

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Prolactin cell adenomas of the human pituitary. Morphologic features of prolactin cells in the nontumorous portions of the anterior lobe

6 December 2022

73

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine

6 December 2022

74

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture

6 December 2022

75

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas

6 December 2022

76

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly

6 December 2022

77

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly

6 December 2022

78

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro

6 December 2022

79

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein

6 December 2022

82

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Immunohistochemical examination of the paraadenomatous "normal" pituitary. An evaluation of prolactin cell hyperplasia

6 December 2022

84

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Effects of dopamine infusion on pituitary hormone secretion in humans

6 December 2022

85

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

6 December 2022

87

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses

6 December 2022

88

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

The American Journal of Pathology

6 December 2022

89

134

605

Lloyd R.V.

1989

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Effects of bromocriptine on pituitary tumour size

6 December 2022

92

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Studies on the Mechanism of the Dopamine-Mediated Inhibition of Prolactin Secretion1

6 December 2022

93

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Comparative Study of Human Fetal, Normal Adult, and Somatotropic Adenoma Pituitary Function in Tissue Culture*

6 December 2022

94

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine inhibits prolactin and growth-hormone release by human pituitary tumours in culture

6 December 2022

95

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Adenosine 35′5′-Monophosphate Derivatives Increase Prolactin Synthesis and Prolactin Messenger Ribonucleic Acid Levels in Ergocryptine-Treated Pituitary Cells*

6 December 2022

98

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Pathophysiology of Acromegaly*

6 December 2022

100

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

6 December 2022

102

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.

6 December 2022

103

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size

6 December 2022

109

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Resistance to bromocriptine in prolactinomas

6 December 2022

110

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.

6 December 2022

112

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma

6 December 2022

113

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clinical and molecular studies of a thyrotropin-secreting pituitary adenoma

6 December 2022

116

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man

6 December 2022

117

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Morphological Evidence for the Presence of Arteries in Human Prolactinomas*

6 December 2022

118

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Abnormal regulation of prolactin secretion after successful surgery for prolactin-secreting pituitary tumours

6 December 2022

119

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months

6 December 2022

120

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Gonadotroph cell adenomas of the pituitary

6 December 2022

125

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Evidence for dopaminergic control of circadian variations in thyrotropin secretion.

6 December 2022

127

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase

6 December 2022

128

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine

6 December 2022

129

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine treatment of acromegaly

6 December 2022

135

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Rapid regression of pituitary prolactinomas during bromocriptine treatment

6 December 2022

136

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Calcium, cyclic AMP and hormone action

6 December 2022

137

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Persistent defect in regulation of prolactin secretion after successful pituitary tumor removal in women with the galactorrhea-amenorrhea syndrome

6 December 2022

138

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine

6 December 2022

141

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Long-term treatment of acromegaly with bromocriptine

6 December 2022

145

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

Bromocriptine in management of large pituitary tumours

6 December 2022

146

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.1991.TB00928.X

6 December 2022

Identifiers

1 reference

18 August 2017

1 reference